氟伐他汀联合苯扎贝特治疗冠心病合并混合型高脂血症的临床观察

目的：观察氟伐他汀联合苯扎贝特治疗冠心病合并混合型高脂血症的调脂效果及安全性。方法：将我中心332例高脂血症患者随机分为4组，每组83例。A组口服氟伐他汀40mg·d^-1，B组口服苯扎贝特400mg·d^-1，C组口服氟伐他汀20mg·d^-1＋苯扎贝特400mg·d^-1，D组口服氟伐他汀40mg·d^-1＋苯扎贝特400mg·d^-1，4组疗程均为24周。观察患者血脂变化及不良反应等。结果：与治疗前比较，4组低密度脂蛋白胆固醇（LDL-C）均显著降低，高密度脂蛋白胆固醇（HDL-C）显著上升（P〈0．05），且治疗后A、C、D组LDL-C显著优于B组（P〈0．001），B、C、D组HDL-C显著优于A组（P〈0．001）。其中，D组各项指标治疗效果最佳。4组患者均具有较好的耐受性，均未见严重不良反应发生。结论：氟伐他汀40mg联合苯扎贝特400mg治疗混合型高脂血症疗效较好，能有效纠正各项临床指标，具有较好的安全性和耐受性。

Clinical Observation of Fluvastatin Combined with Bezafibrate in the Treatment of Coronary Disease Complicating with Combined Hyperlipidemia

OBJECTIVE： To observe the effect and safety of fluvastatin combined with bezafibrate in the treatment of coronary disease complicating with combined hyperlipidemia. METHODS： 332 patients with hyperlipidemia in our hospital were randomly divide into 4 groups, while each group had 83 cases. Group A was given oral administration of fluvastatin 40 mg·d^-1, group B oral administration of bezafibrate 400 mg·d^-1, group C oral administration of fluvastatin 20 mg·d^-1＋bezafibrate 400 mg·d^-1, and group D oral administration of fluvastatin 40 mg·d^-1bezafibrate 400 mg·d^-1. Treatment course lasted for 24 weeks. The blood fat and ADRs of patients＇ were observed. RESULTS： Compared with before treatment, LDL-C level of 4 groups decreased significantly （P〈0.05）, HDL-C level increased significantly （P〈0.05）, LDL-C of group A, C, D were better than that of group B （P〈 0.001 ）, and HDL-C of group B, C, D were better than group A （P〈0.001）. Therapeutic efficacy of group D was the best among 4 groups. All groups had good tolerance and no adverse drug reaction occurred. CONCLUSION： Fluvastatin 40 mg combined with bezafibrate 400 mg is effective in the treatment of combined hyperlipidemia and can correct clinical index effectively. It has preferable safety and tolerance.